Recent advance in lipid management: Focus on PCSK9I (Proprotein Convertase Subtilisin/ Kexin 9 Inhibitors).
This review discusses recent advances in lipid management, focusing on a new class of drugs known as pcsk9i (proprotein convertase subtilisin/ kexin 9 inhibitors. It describes the basic and clinical pharmacology of these drugs.